Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704099 | 0.94 | HRH3 (0.40) | HRH3ALDH1A1GRM5DPP4 | |
| SCHEMBL973611 | 0.91 | LMNA (0.37) | ACKR3GRM5BTKAKT1 | |
| SCHEMBL971760 | 0.90 | SMN1; SMN2 (0.39) | ACKR3HRH3ALDH1A1SMPD3GRM5 | |
| SCHEMBL972950 | 0.89 | GRM5 (0.40) | HRH3SMPD3GRM5 | |
| SCHEMBL973545 | 0.88 | BTK (0.45) | ACKR3HRH3SMPD3GRM5BTK | |
| SCHEMBL974372 | 0.86 | SMPD3 (0.36) | ACKR3SMPD3BTKAKT1 | |
| SCHEMBL2855060 | 0.85 | ALDH1A1 (0.43) | ACKR3HRH3ALDH1A1SMPD3BTK | |
| SCHEMBL4701477 | 0.84 | SMN1; SMN2 (0.42) | HRH3ALDH1A1GRM5 | |
| SCHEMBL971906 | 0.84 | SMPD3 (0.41) | ACKR3HRH3SMPD3GRM5BTK | |
| SCHEMBL974804 | 0.84 | SMN1; SMN2 (0.41) | ACKR3HRH3ALDH1A1SMPD3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | claimed |
| EP-1968957-B1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-20 | — | — | EP | claimed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | claimed |
| WO-2007079960-A9 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | WO | claimed |
| US-7871999-B2 | Substituted thiazoles and their use for producing drugs | GRUENENTHAL GMBH (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1968957-B1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-07-09 | — | — | US | disclosed |
| WO-2007079960-A9 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2008-10-23 | — | — | WO | disclosed |
| EP-1968957-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007079960-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176756-A1 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS | TPMT, SLC5A2, DPP4 | ACKR3 2993/4885HRH3 2654/4885ALDH1A1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.